NasdaqCM - Nasdaq Real Time Price USD

Optimi Health Corp. (OPTH)

2.5000 +0.0900 (+3.73%)

As of 10:46:24 AM EST. Market Open.

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

Optimi Health Establishes Optimi Australia Pty Ltd as Dedicated Distribution and Business Development Entity

GlobeNewswire 7d ago

OPTH
+3.73%
Optimi Health Completes MDMA Production for Phase 3 PTSD Trial in Canada, MAPS Trial in Israel and Commercial Supply in Australia

GlobeNewswire 13d ago

OPTH
+3.73%
Optimi Health to Present at the ThinkEquity Conference

GlobeNewswire 26d ago

OPTH
+3.73%
Optimi Health Completes Psilocybin Production for Phase 2 MDD Trial

PREMIUM
MT Newswires 1mo ago

OPTH
+3.73%
Optimi Health Completes Psilocybin Production for Health Canada-Approved Phase 2 MDD Trial and Commercial TRD Supply

GlobeNewswire 1mo ago

OPTH
+3.73%
Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer

GlobeNewswire 1mo ago

OPTH
+3.73%
Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Market Exclusive 1mo ago

OPTH
+3.73%
LLY

CURA.TO
Elon Musk Once Said Psychedelics Could Help PTSD — Now FDA Holds Hearing as Optimi Health Advances MDMA Trial

Benzinga 1mo ago

OPTH
+3.73%
Optimi Health to Initiate Phase 2 Clinical Trial Evaluating Psilocybin-Assisted Therapy for Major Depressive Disorder

GlobeNewswire 1mo ago

OPTH
+3.73%
Optimi Health to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

GlobeNewswire 1mo ago

OPTH
+3.73%
Optimi Health Establishes $100 Million Equity Facility as Psychedelic Commercialisation Advances

Simply Wall St. 2mo ago

OPTH
+3.73%
Optimi Health Establishes Discretionary Equity Facility

GlobeNewswire 2mo ago

OPTH
+3.73%

Performance Overview

Return	OPTH	S&P/TSX Composite index (^GSPTSE)
YTD	-54.55%	+12.75%
1-Year	-54.55%	+18.73%
3-Year	-54.55%	+83.06%

U.S. markets close in 4h 55m

Optimi Health Corp. (OPTH)

Optimi Health Establishes Optimi Australia Pty Ltd as Dedicated Distribution and Business Development Entity

Optimi Health Completes MDMA Production for Phase 3 PTSD Trial in Canada, MAPS Trial in Israel and Commercial Supply in Australia

Optimi Health to Present at the ThinkEquity Conference

Optimi Health Completes Psilocybin Production for Phase 2 MDD Trial

Optimi Health Completes Psilocybin Production for Health Canada-Approved Phase 2 MDD Trial and Commercial TRD Supply

Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Elon Musk Once Said Psychedelics Could Help PTSD — Now FDA Holds Hearing as Optimi Health Advances MDMA Trial

Optimi Health to Initiate Phase 2 Clinical Trial Evaluating Psilocybin-Assisted Therapy for Major Depressive Disorder

Optimi Health to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Optimi Health Establishes $100 Million Equity Facility as Psychedelic Commercialisation Advances

Optimi Health Establishes Discretionary Equity Facility